PCVX (Vaxcyte) 3-Year Revenue Growth Rate : 0.00% (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Vaxcyte 3-Year Revenue Growth Rate?

Vaxcyte's Revenue per Share for the three months ended in Sep. 2024 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Competitive Comparison of Vaxcyte's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Vaxcyte's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vaxcyte's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxcyte's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Vaxcyte's 3-Year Revenue Growth Rate falls into.

Vaxcyte 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Vaxcyte (NAS:PCVX) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Vaxcyte 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Vaxcyte's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Vaxcyte Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxcyte Inc (NAS:PCVX) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

5VA:Germany

Address

825 Industrial Road, Suite 300, San Carlos, CA, USA, 94070

Website

https://www.vaxcyte.com

Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.

Executives

Jim Wassil	officer: Chief Operating Officer	C/O VAXCYTE, INC., 353 HATCH DRIVE, FOSTER CITY CA 94404
Grant Pickering	director, officer: President & CEO	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Andrew Guggenhime	officer: CFO, CBO	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Mikhail Eydelman	officer: SVP, Gen Counsel & Corp Sec	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, SUITE 300, SAN CARLOS CA 94070
Teri Loxam	director	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Elvia Cowan	officer: See Remarks Section	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, SUITE 300, SAN CARLOS CA 94070
Halley E Gilbert	director	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Heath Lukatch	director	326 BOLLAY DRIVE, GOLETA CA 93117
Jeff Fairman	officer: VP, Research	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Paul Sauer	officer: SVP Process Dev, Manufacturing	C/O VAXCYTE, INC., 825 INDUSTRIAL DRIVE, STE. 300, SAN CARLOS CA 94404
Michael E. Kamarck	director	C/O UNILIFE CORPORATION, 250 CROSS FARM LANE, YORK PA 17406
Carlos V Paya	director	C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Harpreet S. Dhaliwal	officer: SVP Cml Mfg & Supply Chain	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Anne S Drapeau	director	C/O IRON MOUNTAIN INCORPORATED, ONE FEDERAL STREET, BOSTON MA 02110
Jane Wright Mitchell	officer: General Counsel	C/0 ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063